Russia’s Federal Antimonopoly Service (FAS) found that pharmaceutical companies Axelpharm and Akrikhin violated competition protection law. This is stated in the following message: website services.
“Organizations are ordered to transfer illegally obtained income exceeding 1.5 billion rubles to the budget,” the message says.
According to the service, pharmaceutical companies have put into circulation generics of the drugs Ruxolitinib and Fordiglyf, the originals of which are protected by patents until 2028. The FAS stated that Axelpharm should return 960.8 million rubles to the budget, and Akrikhin – 577.7 million rubles.
FAS Russia in July excited A lawsuit was filed against the pharmaceutical company Akrikhin, which was accused of violating the Law on the Protection of Competition. In April 2024, Akrikhin put into circulation 22 batches of the drug for the treatment of diabetes mellitus Fordiglyf, an analogue of the British-Swedish company AstraZeneca’s original drug Forxiga. The manufacturer of Forxiga assessed that Akrikhin’s actions infringed a patent valid until 2028; He noted that infringement of patent rights threatens people’s health for the sake of quick profit.
AstraZeneca in August controversial Patent for an analogue of the anti-oncology drug Tagrisso, registered by the Russian company Axelpharm. We are talking about the drug Osimertinib.
Previously at FAS clarified Road cartel for 14.9 billion rubles.